lifestyle.ubi-interactive.com

Author: Kyverna Therapeutics, Inc.

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

April 21, 2026
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

April 20, 2026
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

April 9, 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

March 5, 2026
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences

March 3, 2026
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

February 24, 2026
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

February 10, 2026